IN8bio Inc (INAB) News

IN8bio to Present at Biotech Showcase 2025 in San Francisco

NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute...

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical...

Form 8-K - Current report

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

50% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median...

Form EFFECT - Notice of Effectiveness